Wall Street is experiencing heightened anxiety over AI’s impact, particularly as investors overlook potential opportunities in the pharmaceutical sector. Notably, AI could reduce drug development timelines from 10-15 years to as little as six years, significantly increasing revenue potential for drug companies.
The BlackRock Health Sciences Term Trust (BMEZ), currently offering an 8.8% dividend and trading at an 11.4% discount to its net asset value, presents a strong investment opportunity. The fund includes big pharmaceutical players like Gilead Sciences, which is investing heavily in AI to enhance its R&D processes, reflecting an industry poised for growth as AI innovations are applied.
As of now, Gilead is advancing 25 treatments in Phase 1 trials and has committed $5.7 billion to R&D—19% of its revenue. This AI integration is anticipated to yield significant returns as the company pushes new drugs to market faster, capitalizing on AI’s potential to bolster both product cycles and cash flows.
